BioPorto Diagnostics A/S

BioPorto Diagnostics A/S is a Denmark-based in vitro diagnostics company specializing in kidney health biomarkers for early detection of acute kidney injury (AKI). The company develops and manufactures clinical diagnostic tests, ELISA kits for research applications, monoclonal antibodies, and rapid assays targeting nephrology and critical care markets. BioPorto's flagship product, the NGAL Test™, is CE-marked for EU clinical use and FDA-cleared for pediatric AKI risk assessment in the US. The NGAL biomarker enables early identification of kidney damage, potentially preventing irreversible injury and guiding timely clinical intervention. BioPorto also supplies human and animal NGAL ELISA kits for preclinical and Phase 1 clinical research. The company collaborates with major diagnostic manufacturers including Roche Diagnostics and Siemens Healthcare to distribute products via clinical chemistry analyzers and laboratory platforms. With deep expertise in assay development and monoclonal antibody production, BioPorto serves hospitals, clinical laboratories, research institutions, and pharmaceutical companies focused on improving kidney care outcomes.